Profound Medical Corp. (PROF) Q3 2026 earnings review
Profound Medical machine sales jump, but recurring procedure revenue stalls
Profound Medical, a maker of MRI-guided ultrasound systems that destroy prostate tissue without incisions, rebounded via machine sales while recurring procedure revenue stood still. Total sales rose 86% to $9.8 million — or 27% by our math without $3.1 million of delayed June shipments — and cash burn fell by more than half. Chief executive Arun Menawat firmed the full-year outlook to at least $25 million before handing the role to president Richard Fabian in January.
| Revenue excluding Q2 shipment delay | $6.7M +27% from a year ago by our math (reported: $9.8M, +86%) |
|---|---|
| Recurring procedure and service revenue | $4.1M +1% from a year ago |
| Operating cash burn | $5.0M down 56% from last quarter |
| Full-year revenue outlook | Raised floor at least $25M (+55% from 2025) |
⚖️ Verdict: 🟢 Bullish
The story got better because the company cleared its shipping backlog, won a US distribution deal with Cook Medical, and secured higher 2027 Medicare pay for surgery centers. Those wins remove a major reimbursement risk and make the full-year revenue target achievable after two years of missed plans. The bad news: recurring sales from single-use treatment kits grew only 1% from a year ago despite 46% more installed machines, and management dropped its two-quarter-old usage metric.
The question now is whether hospitals are actually using the machines they buy or just stocking up on equipment. If procedure demand is building, recurring revenue will climb alongside the larger 98-system base; if hospitals face scheduling bottlenecks, disposable sales will stay stuck near $4 million. Fourth-quarter recurring revenue and one-year cancer trial data in December will tell.
🐂 Bull Case
Equipment Sales and Delayed Shipments Drove the Quarter
Profound Medical sells TULSA-PRO, an ultrasound system that destroys prostate tissue inside a magnetic resonance imaging (MRI) scanner. After missing the second quarter because $3.1 million of shipments slipped past June, the medical device maker recognized those orders in the third quarter and saw machine sales jump nearly fivefold.
- Total revenue: $9.8 million, up 86% from a year ago, or 27% by our math without the $3.1 million shipment delay
- Capital equipment sales: $5.7 million, up 368% from $1.2 million a year ago
- Installed base: 98 systems, up by 14 in the quarter vs 6 across the entire first half
- Qualified sales pipeline (late-stage deals in verification, negotiation or contracting): $79.2 million, up 13% from last quarter
Clearing the shipping backlog eased a standing worry about installation delays, and chief executive Arun Menawat raised the full-year target to at least $25 million. Still, Menawat said the installed base will finish the year "well over 100" systems, which steps back from an earlier 120-system goal.
What to watch: fourth-quarter revenue against the $7.4 million minimum implied by the full-year outlook. Meeting that figure without help from delayed shipments will show that the $79.2 million pipeline is converting on schedule.
Medicare and Cook Medical Open Surgery Centers
Urologists often struggle to book time on hospital MRI scanners, and a proposed Medicare cut threatened to make outpatient surgery centers unprofitable for TULSA-PRO. This quarter lifted both hurdles: Medicare finalized its 2027 rules with higher outpatient pay, and Cook Medical agreed to distribute TULSA-PRO inside turnkey MRI suites across the United States.
Menawat said "reimbursement in ASCs is going to be about 11,400 plus" under the final 2027 Medicare rule, matching hospital robotic surgery rates and reversing a proposed cut to $6,866. Meanwhile, Cook will buy TULSA-PRO machines at a set price while Profound keeps direct sales of single-use devices and service contracts.
The company also added 10.7 million insured lives in the quarter — bringing its total to 35–40 million, chief commercial officer Thomas Tamberrino said — and signed a physician-education deal with imaging firm Telix Pharmaceuticals. However, TULSA-PRO still awaits US regulatory clearance for Siemens scanners, and Menawat expects Cook sales to show up only in the second half of 2027.
What to watch: one-year cancer-control data from the CAPTAIN trial, which compares TULSA-PRO with robotic surgery, at a radiology conference in late November. Strong results would help Tamberrino's team win national private insurance contracts in 2027.
Higher Revenue Cut Operating Cash Burn in Half
Profound has lost money every quarter while building its sales force, and operating cash use hit $11.3 million in the second quarter. In the third quarter, higher machine sales and firmer pricing lifted gross margin to 78.1%, up 3.8 percentage points from a year ago as the cost of making products fell from 25.7% to 21.9% of revenue.
Operating expenses rose 21% to $15.5 million on higher headcount, sales commissions and engineering consulting, even as CAPTAIN trial costs fell. Because revenue grew four times as fast, selling and administrative costs dropped by 41.8 percentage points of revenue, and research and development fell by 43.4 points, cutting operating cash burn by 56% from last quarter to $5.0 million.
What to watch: fourth-quarter operating cash burn and selling expenses. Incoming chief executive Richard Fabian warned that new support hires take two quarters to pay off, so holding cash burn near $5 million will test spending discipline.
🐻 Bear Case
Recurring Sales Stalled and Management Dropped Its Usage Metric
"Our priority is to convert growing physician interest, broader payer coverage and clinical evidence into system placements and recurring procedure revenue," Menawat said. Recurring revenue comes from single-use treatment kits and warranties, and Profound's long-term plan relies on doctors performing more procedures on every installed machine.
That recurring stream barely moved against last year. While the installed base grew 46% from 67 systems a year ago to 98, recurring revenue crept up 1.0% from $4.07 million to $4.11 million. At the same time, Profound stopped reporting its INDEX20 score — a measure of quarterly procedures at 20 established sites — just two quarters after introducing it.
Menawat said "20 Index was kind of losing its original purpose" as the base neared 100 sites, and noted that benign enlarged prostate cases were only 2% of procedures (plus 9% combined with cancer). Dropping the metric right after it fell 12% in the second quarter leaves investors unable to see whether older hospitals are actually treating more men.
What to watch: fourth-quarter recurring revenue and the replacement usage metric Fabian promised to build. If recurring sales stay stuck near $4 million while installed systems pass 100, newly placed machines are sitting idle after launch.
Cash Burn and Debt Maturity Leave Dilution on the Table
Profound ended September with $33.3 million in cash, down from $59.7 million at the end of 2025 after burning $24.9 million in operating cash over nine months. Meanwhile, $4.5 million of debt moved into current liabilities because it comes due within a year.
Menawat said current cash and sales will fund the business for at least 12 months, adding, "While we have no immediate plans to raise capital, we will opportunistically evaluate both dilutive and non-dilutive financing opportunities." Because the company still loses $5.0 million in cash in its best quarter and plans to hire more support staff, another share sale remains a clear risk.
What to watch: year-end cash and how Profound handles the $4.5 million current debt maturity by March 2027. A cash balance below $25 million would tighten lender rules and push the company toward selling more shares.
👓 Other Themes
President Richard Fabian Will Become Chief Executive in January
Profound named president Richard Fabian, a 29-year medical device veteran and former chief executive of FUJIFILM Sonosite, to succeed Arun Menawat as chief executive on January 14, 2027. Menawat will become executive chairman on his 72nd birthday. In addition, the board promoted controller Matthew Sobczyk to permanent finance chief — settling questions after the prior finance chief's unexplained absence last quarter — and appointed Penumbra strategy executive Jason Mills as a director.
💲 Other KPIs
Uncollected customer bills rose 46.5% from $7.5 million at the end of 2025 (including non-current bills), eating up $3.9 million of operating cash over the first nine months. Because the medical device maker records machine sales upon shipment while hospitals take two to four months to install them, receivables remain larger than quarterly revenue.
Deferred revenue — cash customers have paid upfront for extended warranties and services not yet delivered — rose 85.8% from $0.83 million at year-end 2025, jumping from $0.96 million in the second quarter. Commercial chief Thomas Tamberrino said service contracts are growing as more customers buy machines outright rather than leasing them.
Share count rose 21.4% from 30.1 million a year ago because the Toronto-based group raised $42.5 million in gross proceeds through US and Canadian stock sales in December 2025. That higher share count narrowed the quarterly loss per share by 19% (from $0.26 to $0.21) even though total net loss improved by only 3%.
🔮 Guidance
Raised. "Our full year revenue outlook has improved from approximately $25 million to at least that level," Menawat said, which equals at least 55.3% growth for the year. By our math, that floor leaves at least $7.35 million for the fourth quarter — up 23.0% from a year ago, but down 25.2% from the third quarter's shipment-boosted peak.
Unchanged. Profound kept its full-year gross margin floor at 70% or higher, and Menawat told analysts to model 70% to 75% over time even as Cook Medical distributor sales begin. Nine-month gross margin already stands at 76.3% after hitting 78.1% in the third quarter, so the annual floor is well below current rates.
❓ Key Questions
What was per-system procedure volume across all 98 installed sites?
Management retired its INDEX20 usage metric after two quarters, and third-quarter recurring revenue grew just 1% from a year ago despite 46% more installed systems. Without a replacement number, investors cannot tell whether older sites slowed down or new installs are taking longer to start.
How many TULSA-PRO systems sit inside the $79.2 million pipeline?
Profound switched its pipeline disclosure from machine counts (110 systems at year-end 2025) to dollars two quarters ago, and Tamberrino noted the dollar figure now mixes machines with initial disposable orders. Knowing the unit count would show how fast hospital equipment demand is actually growing.
How will Profound handle its $4.5 million current debt maturity?
Long-term debt of $4.51 million moved into current liabilities as its 2027 maturity approaches, while lender rules require a minimum cash cushion. Management has not said whether it will pay off, refinance or expand that credit line.
When will the FDA clear TULSA-PRO for Siemens Free.Max scanners?
Profound previously targeted clearance for the combined Siemens scanner package in 2025 and then early 2027, but this quarter's release only mentioned ongoing regulatory work in a footnote. A firm date matters because dedicated interventional MRI suites depend on scanner compatibility.